EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

A multicenter, phase II trial of GC1118 , a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification

Seung Won Choi iD, Hyun Ae Jung, Hee-Jin Cho, Tae Min Kim iD, Chul-Kee Park iD, Do-Hyun Nam, Se-Hoon Lee

Cancer Medicine · 2023

DOI: 10.1002/cam4.6213 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2023. Verfasst von Seung Won Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, School of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents, Brain Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We evaluated the therapeutic efficacy of GC1118, a novel anti‐epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification.

Methods

This study was a multicenter, open‐label, single‐arm phase II trial. Recurrent GBM patients with EGFR amplification were eligible: EGFR amplification was determined using fluorescence in situ hybridization analysis when a sample had both the EGFR/CEP7 ratio of ≥2 and a tight cluster EGFR signal in ≥10% of recorded cells. GC1118 was administered intravenously at a dose of 4 mg/kg once weekly. The primary endpoint was the 6‐month progression‐free survival rate (PFS6). Next‐generation sequencing was performed to investigate the molecular biomarkers related to the response to GC1118.

Results

Between April 2018 and December 2020, 21 patients were enrolled in the study and received GC1118 treatment. Eighteen patients were eligible for efficacy analysis. The PFS6 was 5.6% (95% confidence interval, 0.3%–25.8%, Wilson method). The median progression‐free survival was 1.7 months (range: 28 days–7.2 months) and median overall survival was 5.7 months (range: 2–22.0 months). GC1118 was well tolerated except skin toxicities. Skin rash was the most frequent adverse event and four patients experienced Grade 3 skin‐related toxicity. Genomic analysis revealed that the immune‐related signatures were upregulated in patients with tumor regression.

Conclusion

This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune‐mediated antitumor efficacy of GC1118.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaAntineoplastic AgentsBrain NeoplasmsHumansIn Situ Hybridization, FluorescenceNeoplasm Recurrence, LocalAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalChronic Disease

Stichwörter der Autor:innen

EGFRglioblastomaimmune responsemonoclonal antibody

Substanzen

GC1118Antibodies, Monoclonal, HumanizedAntineoplastic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Neurosurgery, School of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
  • Department of Medicine, Division of Hematology-Oncology, School of Medicine, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
  • Department of Biomedical Convergence Science and Technology, Kyungpook National University, Daegu, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurosurgery, Seoul National University Hospital, College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Seung Won Choi, Tae Min Kim, Chul-Kee Park

Zitieren

APA

Choi, S. W., Jung, H. A., Cho, H. J., Kim, T. M., Park, C. K., Nam, D. H., & Lee, S. H. (2023). A multicenter, phase II trial of GC1118 , a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification. Cancer Medicine. https://doi.org/10.1002/cam4.6213

Vancouver

Choi SW, Jung HA, Cho HJ, Kim TM, Park CK, Nam DH, et al. A multicenter, phase II trial of GC1118 , a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification. Cancer Medicine. 2023. doi:10.1002/cam4.6213

BibTeX
@article{Choi2023,
  author = {Choi, Seung Won and Jung, Hyun Ae and Cho, Hee-Jin and Kim, Tae Min and Park, Chul-Kee and Nam, Do-Hyun and Lee, Se-Hoon},
  title = {A multicenter, phase II trial of GC1118 , a novel anti‐EGFR antibody, for recurrent glioblastoma patients with EGFR amplification},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6213}
}
Kostenlos starten →